Intrinsic Value of S&P & Nasdaq Contact Us

Orexo AB (publ) ORXOF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • SE • USD

SharesGrow Score
18/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Orexo AB (publ) (ORXOF) reported total assets of $1.3B and total liabilities of $810.16M for quarter ending 2025-12-31, resulting in total equity of $489.37M.

The company held $910.11M in cash and short-term investments. Total debt stood at $490.97M, with net debt of $-419.15M. The Debt-to-Equity (D/E) ratio was 1 (moderate).

Current ratio is 3.7, indicating strong short-term liquidity. Interest coverage is -8.5x (weak).

Criteria supported by this page:

  • HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
  • MOAT (0/100) — Total assets $1.3B and equity $489.37M support the company's competitive scale

Overall SharesGrow Score: 17/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score
18/100
SG Score
View full scorecard →
VALUE
N/A
No coverage
FUTURE
N/A
No coverage
PAST
0/100
→ Income
~
HEALTH
50/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
0/100
Proven by this page
GROWTH
30/100
→ Income
INCOME
10/100
→ Income
Orexo AB (publ) Balance Sheet History
Metric Q4 FY2025 Q3 FY2025 Q2 FY2025 Q1 FY2025
Total Assets $1.3B$515.03M$533.4M$529M
Total Liabilities $810.16M$737.69M$730.4M$690.3M
Total Debt $490.97M$487.92M$495.6M$483.9M
Cash & Investments $910.11M$104.87M$121.3M$119.1M
Total Stockholders Equity $489.37M$-223M$-197M$-161.3M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message